Gene Editing Corrects In Vitro a G > A GLB1 Transition from a GM1 Gangliosidosis Patient
The CRISPR Journal · 2023
DOI: 10.1089/crispr.2022.0045 ↗Kurz gefasst
Fachartikel in der Zeitschrift The CRISPR Journal, 2023. Verfasst von Delphine Leclerc und 17 weiteren Autor:innen. Beteiligte Einrichtung: INSERM U1242, OSS, Univ Rennes, Rennes, France. Hauptthemen laut MEDLINE: Gangliosidosis, GM1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ganglioside-monosialic acid (GM1) gangliosidosis, a rare autosomal recessive disorder, is frequently caused by deleterious single nucleotide variants (SNVs) in GLB1 gene. These variants result in reduced β-galactosidase (β-gal) activity, leading to neurodegeneration associated with premature death. Currently, no effective therapy for GM1 gangliosidosis is available. Three ongoing clinical trials aim to deliver a functional copy of the GLB1 gene to stop disease progression. In this study, we show that 41% of GLB1 pathogenic SNVs can be replaced by adenine base editors (ABEs). Our results demonstrate that ABE efficiently corrects the pathogenic allele in patient-derived fibroblasts, restoring therapeutic levels of β-gal activity. Off-target DNA analysis did not detect off-target editing activity in treated patient's cells, except a bystander edit without consequences on β-gal activity based on 3D structure bioinformatics predictions. Altogether, our results suggest that gene editing might be an alternative strategy to cure GM1 gangliosidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- INSERM U1242, OSS, Univ Rennes, Rennes, France.
- CHU Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, FHU GenOMEDS, ERN ITHACA, Hôpital Sud, Rennes, France.
- INSERM, EHESP, IRSET-UMR_S, 1085, Université Rennes 1, Rennes, France.
- Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France.
- Department of Pediatrics, Competence Center of Inherited Metabolic Disorders, Rennes Hospital, Rennes, France.
- Laboratoire de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, Rennes, France.
ORCID-Profile: Leif A Eriksson, David Gilot
Zitieren
APA
Leclerc, D., Goujon, L., Jaillard, S., Nouyou, B., Cluzeau, L., Damaj, L., Dubourg, C., Etcheverry, A., Levade, T., Froissart, R., Dréano, S., Guillory, X., Eriksson, L. A., Launay, E., Mouriaux, F., Belaud-Rotureau, M. A., Odent, S., & Gilot, D. (2023). Gene Editing Corrects In Vitro a G > A GLB1 Transition from a GM1 Gangliosidosis Patient. The CRISPR Journal. https://doi.org/10.1089/crispr.2022.0045
Vancouver
Leclerc D, Goujon L, Jaillard S, Nouyou B, Cluzeau L, Damaj L, et al. Gene Editing Corrects In Vitro a G > A GLB1 Transition from a GM1 Gangliosidosis Patient. The CRISPR Journal. 2023. doi:10.1089/crispr.2022.0045
BibTeX
@article{Leclerc2023,
author = {Leclerc, Delphine and Goujon, Louise and Jaillard, Sylvie and Nouyou, Bénédicte and Cluzeau, Laurence and Damaj, Léna and Dubourg, Christèle and Etcheverry, Amandine and Levade, Thierry and Froissart, Roseline and Dréano, Stéphane and Guillory, Xavier and Eriksson, Leif A and Launay, Erika and Mouriaux, Frédéric and Belaud-Rotureau, Marc-Antoine and Odent, Sylvie and Gilot, David},
title = {Gene Editing Corrects In Vitro a G > A GLB1 Transition from a GM1 Gangliosidosis Patient},
journal = {The CRISPR Journal},
year = {2023},
doi = {10.1089/crispr.2022.0045}
}
EUVIMED